Heidelberg Pharma AG
XMUN:HPHA
Heidelberg Pharma AG
XMUN:HPHA
Price:
2.45
EUR
Market Closed
Market Cap:
€114.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
H
|
Heidelberg Pharma AG
XMUN:HPHA
|
DE |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
US |
|
I
|
Inchcape PLC
F:IJCA
|
UK |
|
K
|
Komatsu Ltd
XMUN:KOM1
|
JP |
|
A
|
Aflac Inc
LSE:0H68
|
US |
|
G
|
GlaxoSmithKline PLC
OTC:GLAXF
|
UK |
|
A
|
Amazon.com Inc
DUS:AMZ
|
US |
|
Nippon Building Fund Inc
OTC:NBFJF
|
JP |
|
China Resources Mixc Lifestyle Services Ltd
OTC:CRMLY
|
CN |
|
Lemonade Inc
F:LE0
|
US |
|
Bilibili Inc
LSE:0T3W
|
CN |
|
W
|
Wolters Kluwer NV
F:WOSB
|
NL |
|
E
|
EDP SA
ELI:EDP
|
PT |
|
P
|
Planet Fitness Inc
LSE:0KJD
|
US |
|
F
|
FormFactor Inc
SWB:FMF
|
US |
|
Ecolab Inc
NYSE:ECL
|
US |
|
Delivery Hero SE
XETRA:DHER
|
DE |
|
R
|
Renault SA
XHAN:RNL
|
FR |
|
H
|
Healthequity Inc
SWB:2HE
|
US |
|
Lubelski Wegiel Bogdanka SA
F:UXX
|
PL |
|
B
|
Banco de Sabadell SA
XMUN:BDSB
|
ES |
|
Arca Continental SAB de CV
OTC:EMBVF
|
MX |
|
G
|
Genuine Parts Co
XMUN:GPT
|
US |
|
P
|
PT Trimegah Bangun Persada Tbk
IDX:NCKL
|
ID |
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.4m | 1.9m | 3.7m | 7.3m | 8.5m | 1.7m | 18.5m | 9.9m | 6.8m | 1.5m | |
| (809.1k) | (956.7k) | (2.2m) | (3.7m) | (5.6m) | (4.7m) | (4.7m) | (3.3m) | (1.8m) | (272.4k) | |
| 553.1k | 943.5k | 1.5m | 3.6m | 2.9m | (3m) | 13.8m | 6.6m | 5.1m | 1.2m | |
| (7.1m) | (11.8m) | (13.4m) | (13.9m) | (21.4m) | (23m) | (32.1m) | (27.9m) | (28.9m) | (47m) | |
| (2m) | (2.7m) | (3m) | (3.1m) | (3.6m) | (4m) | (4.8m) | (5.2m) | (6.7m) | (7.6m) | |
| (6.1m) | (9.3m) | (10.7m) | (10.9m) | (18.3m) | (18.8m) | (26.4m) | (28.1m) | (21.8m) | (38.8m) | |
| 939.2k | 263.1k | 240.8k | 149k | 464.3k | (235.4k) | (901.3k) | 5.4m | (339.1k) | (630k) | |
| (6.6m) | (10.9m) | (11.9m) | (10.4m) | (18.5m) | (25.9m) | (18.3m) | (21.3m) | (23.9m) | (45.8m) | |
| (10.6k) | (212.6k) | 62k | 13k | (62.8k) | (504.6k) | 358.3k | 869.3k | 1.7m | 4.1m | |
| 19.7k | 218k | — | — | 14k | 9k | 2k | 12k | 5k | — | |
| 212k | 107k | 211k | 211k | 209k | 300k | 115k | 86k | 2.8m | 532k | |
| 0 | — | — | — | 400 | — | — | — | 0 | 0 | |
| (6.4m) | (11m) | (11.7m) | (10.1m) | (18.4m) | (26.1m) | (17.8m) | (20.3m) | (19.4m) | (41.2m) | |
| (9.5k) | 0 | 0 | (5k) | 0 | 0 | (1.9m) | 0 | 0 | (1.1m) | |
| (6.4m) | (11m) | (11.7m) | (10.1m) | (18.4m) | (26.1m) | (19.7m) | (20.3m) | (19.4m) | (42.3m) | |
| (6.4m) | (11m) | (11.7m) | (10.1m) | (18.4m) | (26.1m) | (19.7m) | (20.3m) | (19.4m) | (42.3m) | |
| (0.51) | (0.76) | (0.41) | (0.36) | (0.61) | (0.80) | (0.53) | (0.44) | (0.42) | (0.91) |
A growing testing platform nearing break-even but still reliant on external funding
A pre-revenue clinical biotech funding rising trial costs through external capital
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
A rapidly scaled RNAi platform moving from R&D losses to product profitability
Continue HPHA Research
Other Heidelberg Pharma AG listings: